- Home
- PHIO vs LPTX Comparison
PHIO vs LPTX Comparison
Compare PHIO & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- LPTX
- Stock Information
- Founded
- PHIO 2011
- LPTX 2011
- Country
- PHIO United States
- LPTX United States
- Employees
- PHIO N/A
- LPTX N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHIO Health Care
- LPTX Health Care
- Exchange
- PHIO Nasdaq
- LPTX Nasdaq
- Market Cap
- PHIO 10.2M
- LPTX 10.1M
- IPO Year
- PHIO N/A
- LPTX N/A
- Fundamental
- Price
- PHIO $2.18
- LPTX $0.27
- Analyst Decision
- PHIO Strong Buy
- LPTX Hold
- Analyst Count
- PHIO 3
- LPTX 1
- Target Price
- PHIO $10.67
- LPTX N/A
- AVG Volume (30 Days)
- PHIO 2.7M
- LPTX 1.9M
- Earning Date
- PHIO 08-14-2025
- LPTX 08-14-2025
- Dividend Yield
- PHIO N/A
- LPTX N/A
- EPS Growth
- PHIO N/A
- LPTX N/A
- EPS
- PHIO N/A
- LPTX N/A
- Revenue
- PHIO N/A
- LPTX N/A
- Revenue This Year
- PHIO N/A
- LPTX N/A
- Revenue Next Year
- PHIO N/A
- LPTX N/A
- P/E Ratio
- PHIO N/A
- LPTX N/A
- Revenue Growth
- PHIO N/A
- LPTX N/A
- 52 Week Low
- PHIO $0.97
- LPTX $0.22
- 52 Week High
- PHIO $9.79
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- PHIO 40.77
- LPTX 39.15
- Support Level
- PHIO $2.03
- LPTX $0.23
- Resistance Level
- PHIO $2.29
- LPTX $0.35
- Average True Range (ATR)
- PHIO 0.16
- LPTX 0.04
- MACD
- PHIO -0.03
- LPTX -0.01
- Stochastic Oscillator
- PHIO 22.39
- LPTX 26.16
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.